Biotechnology sector performed well on both public and private markets. Large public biotech stocks continued to climb while smaller stocks remained leveled. Private financing deal flow increased substantially, albeit leaving early stage start-ups behind. Biotech sector experienced an overall increase in VC activity during 2Q 2013 and after much less inspiring first quarter. The comeback of VC funding was consistent with strong public markets as well as high, 13, number of completed Life Sciences IPO transactions.
Market Multiples: You Probably (Very Likely) Need to Revisit
The market approach is very popular in valuation. One simply multiples a financial metric, e.g., revenue or EBITDA, by a market multiple. For example, with 5.0x EBITDA multiple, a company with $10 million in EBITDA is worth $50 million. Comparable publicly traded companies or transactions (the “comparables”) provide the multiples.
November 20, 2025
